Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

A phase I dose escalation trial of stereotactic body radiotherapy and concurrent cisplatin for re-irradiation of unresectable, recurrent carcinomas of the head and neck

Date

09 Oct 2016

Session

Poster display

Presenters

Jimmy Caudell

Citation

Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376

Authors

J. Caudell1, A. Trotti2, J. Kish3, J. Russell3

Author affiliations

  • 1 Radiation Oncology, Moffitt Cancer Center, 33612 - Tampa/US
  • 2 Radiation Oncology, Moffitt Cancer Center, Tampa/US
  • 3 Medical Oncology, Moffitt Cancer Center, 33612 - Tampa/US
More

Resources

Abstract 4174

Background

Locally/Regionally recurrent squamous cancers of the head and neck following radiotherapy are often not amenable to surgical salvage. Conventionally fractionated re-irradiation has been investigated, but survivals are poor. Stereotactic radiotherapy (SBRT) has been proposed as an alternative to conventionally fractionated re-irradiation, but reports to date have not shown significantly improved outcomes. Cisplatin has been shown to sensitize squamous carcinomas to radiotherapy even at doses > 2 Gy. We therefore designed a phase I dose escalation study of SBRT for re-irradiation with concurrent cisplatin (MCC 17799, ClinicalTrials.gov: NCT02158234).

Trial design

This is a phase I, open label, dose escalation safety and tolerability study of SBRT in combination with cisplatin in patients with locally or regionally recurrent squamous cell carcinoma of the head and neck with prior radiotherapy > 45 Gy. Cohort 1 will receive 30 Gy SBRT given every other day for 5 fractions with cisplatin at 15 mg/m2 prior to each fraction. Dose escalation of SBRT to 35 or 40 Gy may occur based on evaluation of dose limiting toxicities up to 90 days following therapy. Approximately 21 patients will be enrolled at our institution. The primary endpoint is to define the maximum tolerated dose of SBRT with concurrent cisplatin. Secondary endpoints include loco-regional control, overall survival, and adverse events.

Clinical trial identification

MCC 17799; ClinicalTrials.gov NCT02158234

Legal entity responsible for the study

N/A

Funding

Department of Radiation Oncology, Moffitt Cancer Center

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings